Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout

Amyloid Beta

StressMarq is pleased to expand their product offering for neurodegenerative disease research! they now offer Amyloid Beta Monomers, Oligomers and Pre-formed Fibrils (PFFs).

StressMarq Biosciences has developed a range of fibrilized and oligomeric protein preparations for use in neurodegenerative disease research, including proteins such as alpha synuclein, tau, amyloid beta, SOD1 and TTR. Our strategic efforts are currently focused on being a world leader in the development and supply of fibrilized proteins (and their derivatives), protein oligomers, and antibodies to these constructs to assist researchers studying Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer’s disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). Aβ oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson’s disease patients with dementia (7).

SKUProduct DescriptionSizes Available
SPR-485Human Amyloid Beta 1-42 Peptide (HFIP, monomeric)100ug 500ug 1mg
SPR-488Human Amyloid Beta 1-42 Oligomers100ug 200ug 500ug
SPR-487Human Amyloid Beta 1-42 Pre-formed Fibrils (PFFs)100ug 200ug 500ug
SPR-492Amyloid Beta Pyroglutamate 3-42 Pre-formed Fibrils100ug  200ug 500ug

*Please inquire for bulk quantities.

Structure

StressMarq’s amyloid beta peptide 1-42 (Aβ42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2).  Our Amyloid Beta 1-42 (Aβ42) Oligomers and  Amyloid Beta 1-42 (Aβ42) Pre-formed Fibrils (PFFs) are generated from Amyloid Beta Peptide 1-42 pre-treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) using a previously published method (1,2).

Upon resuspension in DMSO/dH2O, our Aβ42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. Our Aβ42 PFFs present as long strands when observed under TEM and AFM, and have a unique high molecular weight signal on a Western Blot with an anti-amyloid beta antibody. Our Aβ42 oligomers present as globular oligomers when observed under TEM and AFM, and have a unique dimer/trimer and oligomer signal on a Western Blot with an anti-amyloid beta antibody.

TEM of amyloid beta 1-42 monomers (SPR-485, left), oligomers (SPR-488, middle) and fibrils (SPR-487, right).

AFM of amyloid beta 1-42 monomers (SPR-485, left), oligomers (SPR-488, middle) and fibrils (SPR-487, right).

Toxicity

StressMarq’s Amyloid Beta 1-42 oligomers, pre-formed fibrils (PFFs) and monomeric peptide can be used for neurodegenerative disease research. Our Amyloid Beta 1-42 Oligomers (catalog# SPR-488) and Amyloid Beta 1-42 PFFs (catalog# SPR-487) show a dose-dependent toxicity to primary rat cortical neurons, whereas our Amyloid Beta 1-42 Peptide (monomeric) (catalog# SPR-485) does not show toxicity. The charts below show survival of rat primary cortical neurons 14 days after treatment with different concentrations of (A) monomers, (B) oligomers or (C) fibrils quantified by MAP2 positive neurons and expressed as a percentage of control. Fibrils and respective vehicle controls were initially sonicated in a Bioruptor. Test conditions were run in the same plate as untreated control and vehicle controls, which consisted of buffer without amyloid beta 1-42.

Fibrils and respective vehicle controls were initially sonicated in a Bioruptor. Test conditions were run in the sameplate as untreated control and vehicle controls, which consisted of buffer without amyloid beta 1-42 protein. Data expressed as mean +/- s.e.m. (n=6). A global analysis of the data was performed using a one-way ANOVA followed by Dunnett’s test; ** p<0.01 stats vs control; ## p<0.01, #### p<0.0001 stats vs vehicle control. § represents untreated control condition.

To get a quote for the products or to place an order, please email Sales@2BScientific.com